Search - tctmd.com

Displaying 961 - 980 of 3616

Sort: Relevancy | Date

Presentation TCT 2015

From SYMPLICITY HTN-3 to Ongoing Renal Denervation Studies: What Answers Can We Expect (and Not Expect) From the Ongoing RDN Studies?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane

October 11, 2015

Presentation TCT 2015

Updates From the PARTNER Trials 2: Reports From Selected Substudies

Presenter: Samir R. Kapadia, Jeffrey J. Popma, Darshan Doshi

October 11, 2015

Presentation TCT 2015

Updates From the PARTNER Trials 1: Follow-up From the Inoperable and High-Risk Subgroups

Presenter: Samir R. Kapadia, Jeffrey J. Popma

October 11, 2015

Presentation TCT 2015

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran

October 11, 2015

Presentation TCT 2015

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Shamir R. Mehta

October 11, 2015

Presentation TCT 2015

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Patrick W. Serruys

October 11, 2015

Presentation TCT 2015

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Bayesian Statistics: Can They Be Trusted (or Understood)?!

Presenter: Stuart J. Pocock, Jan Tijssen, Sanjay Kaul

October 11, 2015

Presentation TCT 2015

Considerations and Recommendations for Future Clinical Trials in Device-Based Hypertension Treatments

Presenter: Farrell O. Mendelsohn, William B. White

October 11, 2015

Presentation TCT 2015

Meta-analysis (Standard and Network): The Good, the Bad, and the Ugly

Presenter: Stuart J. Pocock, Jan Tijssen, Somjot S. Brar

October 11, 2015

Presentation TCT 2015

Composite Endpoints/Primary Endpoints/Weighted Endpoints/Patient-Reported Endpoints: How to Choose the Right Endpoint

Presenter: Stuart J. Pocock, Jan Tijssen

October 11, 2015

Presentation TCT 2015

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Presenter: Stuart J. Pocock, Jan Tijssen, David J. Cohen

October 11, 2015

Presentation TCT 2015

Propensity-Matched Analysis: Advantages and Pitfalls (TRANSLATE and PROMETHEUS)

Presenter: Stuart J. Pocock, Jan Tijssen, Usman Baber

October 11, 2015

Presentation TCT 2015

Subgroup Analyses: How Useful or Harmful Are They?

Presenter: Stuart J. Pocock, Jan Tijssen, Darrel P. Francis

October 11, 2015

Presentation TCT 2015

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Presenter: Stuart J. Pocock, Jan Tijssen, John L. Petersen

October 11, 2015

Presentation TCT 2015

Obtaining Informed Consent in Difficult Scenarios Case 3: The Patient With a Language Barrier

Presenter: David A. Cox, Thomas D. Stuckey, Giora Weisz

October 11, 2015

Presentation TCT 2015

Obtaining Informed Consent in Difficult Scenarios Case 2: The Elderly Patient Referred for TAVR

Presenter: David A. Cox, Thomas D. Stuckey, Marian C. Hawkey

October 11, 2015

Presentation TCT 2015

Obtaining Informed Consent in Difficult Scenarios Case 1: Patient Presenting With STEMI

Presenter: David A. Cox, Thomas D. Stuckey, Timothy D. Henry

October 11, 2015

Presentation TCT 2015

How to Become a Well-Respected and Successful Investigator: It's Quality, Not Quantity

Presenter: David A. Cox, Thomas D. Stuckey, James B. Hermiller Jr

October 11, 2015

Presentation TCT 2015

Essentials of Quality and Compliance in Research

Presenter: David A. Cox, Thomas D. Stuckey, Kate Dalton

October 11, 2015

Advertisement

From SYMPLICITY HTN-3 to Ongoing Renal Denervation Studies: What Answers Can We Expect (and Not Expect) From the Ongoing RDN Studies?

Updates From the PARTNER Trials 2: Reports From Selected Substudies

Updates From the PARTNER Trials 1: Follow-up From the Inoperable and High-Risk Subgroups

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

Bayesian Statistics: Can They Be Trusted (or Understood)?!

Considerations and Recommendations for Future Clinical Trials in Device-Based Hypertension Treatments

Meta-analysis (Standard and Network): The Good, the Bad, and the Ugly

Composite Endpoints/Primary Endpoints/Weighted Endpoints/Patient-Reported Endpoints: How to Choose the Right Endpoint

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Propensity-Matched Analysis: Advantages and Pitfalls (TRANSLATE and PROMETHEUS)

Subgroup Analyses: How Useful or Harmful Are They?

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Obtaining Informed Consent in Difficult Scenarios Case 3: The Patient With a Language Barrier

Obtaining Informed Consent in Difficult Scenarios Case 2: The Elderly Patient Referred for TAVR

Obtaining Informed Consent in Difficult Scenarios Case 1: Patient Presenting With STEMI

How to Become a Well-Respected and Successful Investigator: It's Quality, Not Quantity

Essentials of Quality and Compliance in Research

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content